Publications by authors named "Wenjiong Zhou"
On-treatment clinical remission of severe asthma with real-world longer-term biologic use.
J Allergy Clin Immunol Glob
February 2025
Background: There are limited real-world data describing the proportion of patients with severe asthma (SA) who achieve on-treatment clinical remission with long-term biologic treatment.
Objective: Our aim was to examine the proportion and characteristics of adults with SA who achieved clinical remission with biologic therapy.
Methods: CHRONICLE is an observational study of US subspecialist-treated adults with SA.
Article Synopsis
- The study aimed to examine the cardiovascular risks associated with bexagliflozin in individuals with type 2 diabetes (T2D) by analyzing data from 4090 participants involved in controlled trials.
- Results indicated that bexagliflozin did not increase the risk of major adverse cardiovascular events (MACE) compared to a placebo, satisfying safety benchmarks set by regulatory authorities.
- The findings support FDA approval of bexagliflozin for T2D, confirming its safety concerning cardiovascular events.
Article Synopsis
- The study aimed to assess the safety and effectiveness of bexagliflozin when used alongside metformin for treating type 2 diabetes in 317 participants.
- Results showed that bexagliflozin led to a significant reduction in HbA1c levels compared to the placebo, with an impressive mean change of -1.09% versus -0.56%.
- Both systolic blood pressure, fasting plasma glucose, and weight loss also improved in the bexagliflozin group, and fewer serious adverse events were reported compared to the placebo group, indicating that bexagliflozin is a beneficial addition to metformin therapy.
Background: Patients with eosinophilic severe asthma (SA) have an increased risk of asthma exacerbations. Benralizumab is approved for eosinophilic SA, and there is great value in understanding real-world effectiveness.
Objective: The aim of this analysis was to examine the effectiveness of benralizumab in a real-world cohort of subspecialist-treated US patients with eosinophilic SA.
Background: Patients with severe asthma (SA) experience a high disease burden, often precipitated by exposure to disease triggers.
Objective: To evaluate the prevalence and effects of patient-reported triggers on asthma disease burden in a cohort of subspecialist-treated patients with SA in the United States.
Methods: CHRONICLE is an observational study of adults with SA receiving biologics or maintenance systemic corticosteroids or whose disease is uncontrolled on high-dosage inhaled corticosteroids and additional controllers.
Article Synopsis
- The study aimed to compare the safety and effectiveness of bexagliflozin and sitagliptin when used alongside metformin for treating type 2 diabetes in adults.
- A total of 386 participants were randomized to receive either bexagliflozin or sitagliptin, with the main goal of assessing their impact on HbA1c levels after 24 weeks.
- Results showed that bexagliflozin was as effective as sitagliptin for reducing HbA1c and outperformed it in lowering fasting plasma glucose and body mass, with similar rates of adverse events for both medications.
Article Synopsis
- Hyperglycemia can worsen chronic kidney disease (CKD), and traditional diabetes treatments often don't help CKD-related problems; bexagliflozin, an SGLT2 inhibitor, was studied for its potential effectiveness in patients with diabetes and CKD.
- A Phase 3, double-blind trial involved 312 participants with type 2 diabetes and CKD stages 3a and 3b across 54 sites in 4 countries, comparing the effects of 20mg of bexagliflozin to a placebo over 24 weeks.
- Results showed bexagliflozin significantly reduced hemoglobin A1c levels by 0.37%, lowered body weight, systolic blood pressure, fasting
Mantle cell lymphoma (MCL) is a rare, aggressive, incurable B-cell malignancy. Ibrutinib has been shown to be highly active for patients with relapsed/refractory (R/R) MCL. The RAY trial (MCL3001) was a phase 3, randomized, open-label, multicenter study that compared ibrutinib with temsirolimus in patients with R/R MCL.
View Article and Find Full Text PDFAlthough unwanted facial hair often leads to anxiety and avoidance of social situations, evaluation of treatment outcomes in clinical trials has relied largely on measures external to the patient such as the extent of hair growth or an expert physician's assessment, neglecting to include patient reported outcomes (PRO). To assess the level of bother caused by a dermatological condition (hirsutism) and changes brought on by treatment, the instrument ESTEEM was developed by expanding the Bother Assessment in Skin Conditions (BASC) scale to six questions to cover the discomfort felt in four social situations and bother due to removing facial hair. Each question elicits responses on a visual analog scale.
View Article and Find Full Text PDFBackground: Renal transplantation is the standard of care for patients with end-stage renal disease. Although maintenance immunosuppression with calcineurin inhibitors yields excellent one-year survival, it is associated over the long term with high rates of death and graft loss, owing in part to the adverse renal, cardiovascular, and metabolic effects of these agents. The use of potentially less toxic agents, such as belatacept, a selective blocker of T-cell activation, may improve outcomes.
View Article and Find Full Text PDF